Jamie M. Aye

发表

Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high‐grade metastatic tumor with rhabdoid and focal neuroendocrine features

E. Beierle, S. Ranganathan, G. Williams, 2019, Pediatric blood & cancer.

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

Andee M. Beierle, J. Markert, C. Willey, 2022, Cancers.

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

E. Beierle, Raoud Marayati, B. P. Moore, 2019, Translational oncology.

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

E. Beierle, B. P. Moore, J. Stewart, 2018, Scientific Reports.

UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts

A. Hjelmeland, E. Beierle, L. Nan, 2018, Journal of Neuro-Oncology.

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts

E. Beierle, Raoud Marayati, J. Stewart, 2020, Translational oncology.

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth

E. Beierle, Raoud Marayati, J. Stewart, 2021, PloS one.

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

C. Willey, E. Beierle, Raoud Marayati, 2021, Scientific Reports.

Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.

E. Beierle, Raoud Marayati, J. Stewart, 2021, Journal of pediatric surgery.

Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts

E. Beierle, Raoud Marayati, J. Stewart, 2019, Scientific Reports.

Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma

Andee M. Beierle, M. Ohlmeyer, E. Beierle, 2022, Cancers.

Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention

G. Colditz, J. Richman, B. Cherven, 2022, BMC Pediatrics.

Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma

E. Beierle, J. Stewart, E. Mroczek-Musulman, 2018, Oncotarget.

Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.

E. Beierle, J. Stewart, K. Yoon, 2023, Journal of pediatric surgery.

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

Andee M. Beierle, E. Beierle, D. Crossman, 2021, Translational oncology.

PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.

E. Beierle, Raoud Marayati, J. Stewart, 2021, Journal of pediatric surgery.

To Disclose or Not to Disclose: A Case Highlighting the Challenge of Conflicts in Pediatric Disclosure.

J. Wolfe, Isaac Martinez, Emily E. Johnston, 2020, Journal of pain and symptom management.

The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor

C. Willey, E. Beierle, Raoud Marayati, 2019, Oncotarget.

The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.

M. Ohlmeyer, E. Beierle, J. Stewart, 2023, Journal of pediatric surgery.

The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

E. Beierle, J. Stewart, E. Mroczek-Musulman, 2019, Journal of pediatric surgery.

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma12

E. Beierle, J. Stewart, K. Whelan, 2018, Translational oncology.

PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells

E. Beierle, Raoud Marayati, J. Stewart, 2019, PloS one.

Role of Stemness Factors in Neuroblastoma

E. Beierle, Jamie M. Aye, L. Stafman, 2019, Neuroblastoma.

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

E. Beierle, B. P. Moore, J. Stewart, 2018, Scientific Reports.

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

E. Beierle, J. Stewart, Adele P. Williams, 2018, Translational oncology.

Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low‐risk clinical trials: A report from the Children's Oncology Group

J. Palmer, W. Xue, R. Venkatramani, 2021, Pediatric blood & cancer.

Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low‐risk clinical trials

R. Venkatramani, Jamie M. Aye, 2021, Pediatric blood & cancer.

Invasive pulmonary aspergillosis presenting with tracheopleural fistula in a pediatric patient with a history of rhabdomyosarcoma

E. Beierle, Jamie M. Aye, D. Taylor, 2023, Journal of pediatric surgery case reports.

Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group

D. Hawkins, E. Rudzinski, S. Wolden, 2020, Pediatric blood & cancer.

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

E. Beierle, Raoud Marayati, B. P. Moore, 2019, Translational oncology.